In 19th-century physics, the term “singularity” described points where traditional laws of physics no longer applied, symbolizing profound shifts in understanding.
At Singularity, we’re creating inflection points in drug discovery to leverage everyday remedies into new, breakthrough therapeutics.
We See Things Differently.
Singularity is a drug discovery-based research company dedicated to developing novel drug candidates to treat CNS disorders with unmet needs. By applying medicinal chemistry and phenotypic screening to non-regulated, overlooked, or “natural” remedies, we aim to develop new compounds with superior therapeutic potential that can be advanced along a regulatory pathway to better meet the needs of patients.
Singularity’s lead program is a platform established around novel analogs of the key metabolites of Kratom, a traditional therapy that is used to self-medicate a diverse range of CNS ailments by millions in North America and Southeast Asia.
Singularity’s founders have a successful track record identifying and executing on underappreciated drug discovery opportunities. Previously, they founded and led Mindset Pharma to exit to Otsuka Pharmaceuticals. Mindset was a drug discovery business focused on novel psychedelic inspired medicines. Mindset was sold to Otsuka Pharmaceuticals in 2023.
Singularity
[ sin·gu·lar·i·ty ] noun.
Where a change in perspective creates powerful possibilities.
Our Values:
Outcome Centric
Developing treatments that prioritize real world outcomes and patient well being.
Innovation
Continuously pioneering novel drugs from known compounds.
Efficiency
Speed and throughput to rapidly identify viable candidates.
Data-Driven
Generating and leveraging data to guide research.
Collaboration
Working closely with the pharmaceutical and scientific communities and stakeholders.
Contact
To learn more about us, please reach out.
Have questions or want to learn more about Singularity? We’re happy to connect. Please fill out the form and our team will get back to you shortly.